A project to develop safer, novel oral poliovirus vaccines has recruited a new partner, the privately-held Dutch firm Batavia Biosciences.
Funded by the Bill & Melinda Gates Foundation, the project is coordinated by PATH, a non-profit focused on developing health innovations to tackle public health issues.
Novel oral polio vaccine candidates are being developed with the aim of reducing the risk from rare cases of vaccine-associated disease. The novel strains will be stockpiled as protection against possible future outbreaks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze